DELRAY BEACH, Fla., Oct. 12, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Plasma Fractionation Market is projected to reach USD 52.58 billion by 2031 from USD 36.44 billion in 2026, at a CAGR of 7.6% during the forecast period.
Browse 517 market data Tables and 53 Figures spread through 420 Pages and in-depth TOC on "Plasma Fractionation Market - Global Forecast to 2031"
Plasma Fractionation Market Size & Forecast:
- Market Size Available for Years: 2026–2031
- 2026 Market Size: USD 36.44 billion
- 2031 Projected Market Size: USD 52.58 billion
- CAGR (2026–2031): 7.6%
Plasma Fractionation Market Trends & Insights:
- North America accounted for the largest share of 45.5% of the plasma fractionation market in 2025.
- By product, immunoglobulins accounted for the largest share of 51.1% of the plasma fractionation market in 2025.
- By application, therapeutics accounted for 95.0% of the plasma fractionation market in 2025.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=93798284
The plasma fractionation market is expanding as pharmaceutical and biotechnology companies, plasma collection organizations, and healthcare providers increasingly adopt plasma-derived therapies to meet rising clinical demand across immunology, neurology, hematology, critical care, and pulmonology. Plasma-derived products are widely used to manage immunodeficiencies, autoimmune and neurological disorders, bleeding disorders, critical-care conditions, and respiratory diseases. Rising demand for immunoglobulins, coagulation factor concentrates, albumin, protease inhibitors, and other plasma products is accelerating the need for reliable plasma collection and fractionation capacity. In addition, investments in plasma collection infrastructure, advanced fractionation and purification technologies, and manufacturing capacity are expected to further strengthen market growth.
By product, immunoglobulins are expected to register the highest CAGR during the forecast period.
By product, the plasma fractionation market is segmented into immunoglobulins, coagulation factor concentrates, albumin, protease inhibitors, and other plasma products. The immunoglobulins segment is expected to register the highest CAGR over the forecast period, driven by rising demand for IVIG, SCIG, and other immunoglobulins for immunological and neurological conditions. Growing diagnosis of primary immunodeficiencies, autoimmune disorders, and immune-mediated neurological diseases, along with recurring treatment requirements, is supporting demand for immunoglobulin therapies. Expanding plasma collection and fractionation capacity and increasing investments in immunoglobulin manufacturing are further expected to support this segment's growth.
By application, therapeutics is expected to register the highest CAGR during the forecast period.
By application, the plasma fractionation market is segmented into therapeutics and academic & preclinical research. The therapeutics segment is expected to register the highest CAGR over the forecast period, driven by the growing clinical use of plasma-derived products across immunology, neurology, hematology, critical care, pulmonology, hemato-oncology, and rheumatology. Growing demand for immunoglobulins, coagulation factor concentrates, albumin, and protease inhibitors, along with rising prevalence of conditions requiring plasma-derived therapies and increasing healthcare utilization, is supporting the growth of therapeutic applications. Continued investments in plasma collection, fractionation capacity, and manufacturing infrastructure are expected to further support the expansion of this segment.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=93798284
By region, North America accounted for the largest share of the plasma fractionation market in 2025.
In 2025, North America held the largest share of the plasma fractionation market, supported by established plasma collection networks, high utilization of plasma-derived therapies, advanced healthcare infrastructure, and substantial fractionation and manufacturing capabilities. The region benefits from strong demand for immunoglobulins and other plasma-derived products, major market players, and extensive source-plasma collection infrastructure. Continued investments in plasma collection, domestic manufacturing, and advanced fractionation technologies are expected to sustain the region's leading position.
Key Players
Leading players in the Plasma Fractionation companies include CSL (Australia), Takeda Pharmaceutical Company Limited (Japan), Grifols, S.A. (Spain), Octapharma AG (Switzerland), Kedrion S.p.A. (Italy), LFB (France), ADMA Biologics, Inc. (USA), Sanquin (Netherlands), Taibang Biological Group Co., Ltd. (China), GC Biopharma Corporate (South Korea), Hualan Bioengineering Inc. (China), Japan Blood Products Organization (Japan), Emergent (USA), Shanghai RAAS Blood Products Co., Ltd. (China), and Intas Pharmaceuticals Ltd. (India), among others.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=93798284
Plasma Fractionation Market- Investment & funding +Merger & Acquisition
Investment Funding Context
The plasma fractionation market is seeing rising strategic investment, driven by capacity expansion, regional supply security, plasma collection infrastructure development, and growing demand for plasma-derived therapies. Investment activity is increasingly focused on expanding plasma collection networks, establishing and upgrading fractionation facilities, increasing manufacturing capacity, and strengthening regional production capabilities. For instance, in November 2025, CSL announced an investment of approximately USD 1.5 billion in the US to expand manufacturing of plasma-derived therapies, while Takeda announced an investment of approximately USD 230 million in June 2024 to expand plasma-derived therapy production capacity at its Los Angeles facility. These investments underscore the strategic importance of expanding fractionation and manufacturing capacity to meet growing demand and strengthen supply continuity.
Revenue Shift Context
The plasma fractionation market is experiencing a gradual revenue shift toward high-demand plasma-derived products and toward advanced, high-efficiency fractionation and manufacturing capabilities. Immunoglobulins, coagulation factor concentrates, albumin, protease inhibitors, and other plasma-derived products remain important revenue sources, while growing demand for immunoglobulins and specialized therapies is supporting higher-value product categories. The global plasma fractionation market is projected to grow from USD 36.44 billion in 2026 to USD 52.58 billion by 2031, at a CAGR of 7.6%, with incremental revenues supported by rising demand for plasma-derived therapies, expanded plasma collection capacity, and investments in fractionation infrastructure. Meanwhile, conventional fractionation processes continue to form an important manufacturing base, while chromatography, advanced purification, automation, continuous processing, and improved plasma utilization are gaining adoption across plasma collection and manufacturing workflows.
Mergers and Acquisitions
Mergers and acquisitions in the plasma fractionation market are being driven by the need to strengthen plasma collection networks, expand fractionation and manufacturing capacity, and broaden access to plasma-derived product portfolios. Companies are increasingly pursuing strategic transactions to enhance regional supply capabilities, strengthen integrated plasma collection and fractionation operations, and expand their presence in key markets.
PLASMA FRACTIONATION MARKET: MERGERS AND ACQUISITIONS, JANUARY 2023–JULY 2026
Month & Year |
Deal Type |
Company 1 |
Company 2 |
Description |
June 2025 |
Acquisition |
Shanghai RAAS |
Nanyue Biological Pharmaceutical Co., Ltd. |
Shanghai RAAS completed its acquisition of |
September 2024 |
Acquisition |
Kedrion S.p.A (Italy) |
Plasmafera s.r.o. |
Kedrion acquired the Czech plasma-collection |
Company Revenue Share Details
The top five players account for approximately 85-90% of the global plasma fractionation market, indicating a highly consolidated competitive landscape. This concentration reflects the strong installed base, broad product portfolios, recurring reagent and consumable revenues, established customer relationships, and global commercial reach of major market participants. Companies such as CSL (Australia), Grifols, S.A. (Spain), Takeda Pharmaceutical Company Limited (Japan), and Octapharma AG (Switzerland) collectively influence the competitive environment through their plasma collection, fractionation, purification, and plasma-derived product manufacturing capabilities. Their continued focus on expanding fractionation capacity, improving plasma utilization, strengthening product portfolios, and developing advanced manufacturing processes further reinforces the market's consolidation.
Browse Adjacent Market: Biotechnology Market Research Reports &Consulting
See More Latest Medical Devices Reports:
Neurological Biomarkers Market by Offering (Consumables, Instruments), Type (Proteomic, Genomic), Application (Alzheimer's, Parkinson's), End user (Pharma Companies, Clinical Labs) - Forecast to 2030
Cold Plasma Market by Application (Plasma Sterilization, Wastewater Treatment, Wound Healing, Surface Treatment, Coating, Packaging, Thin Film Deposition, Etching, Printing, Skin Treatment), by Regime (Low Pressure, Atmospheric) - Global Forecast to 2031
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/plasma-fractionation-market.asp
Content Source: https://www.marketsandmarkets.com/PressReleases/plasma-fractionation.asp
View original content to download multimedia:https://www.prnewswire.com/news-releases/plasma-fractionation-market-worth-52-58-billion-by-2031---exclusive-report-by-marketsandmarkets-302905629.html
SOURCE MarketsandMarkets
